sodiumdependent phosphate transporter

lifastuzumAb is a humanized IgG1-like monoclonal antibody against NaPi2b, often coupled with the anti-mitotic agent monomethyl auristatin E, which inhibits cell division by blocking the polymerization of microtubule proteins.

PF-06869206 is an oral selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1, IC50: 380 nM).

Lifastuzumab vedotin is an antibody-drug conjugate (ADC) that blocks cell division by inhibiting tubulin polymerization, with potential applications in the research of non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC).

Upifitamab rilsodotin (XMT-1536), an antibody-drug conjugate, specifically targets NaPi2b and is utilized in cancer research, particularly in studies related to ovarian cancer [1] [2].